Exelixis EXEL CABOMETYX — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's cabometyx — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's CABOMETYX — total revenues?
- Exelixis (EXEL) reported CABOMETYX — total revenues of $552.77M in Q1 2026.
- How has Exelixis's CABOMETYX — total revenues changed year-over-year?
- Exelixis's CABOMETYX — total revenues increased by 8.2% year-over-year, from $510.87M to $552.77M.
- What is the long-term trend for Exelixis's CABOMETYX — total revenues?
- Over 4 years (2021 to 2025), Exelixis's CABOMETYX — total revenues has grown at a 19.0% compound annual growth rate (CAGR), from $1.05B to $2.11B.
- What does CABOMETYX — total revenues mean?
- Total revenue generated from the sales of the Cabometyx oncology product.
- How do you interpret CABOMETYX — total revenues?
- An increase indicates strong market demand, successful commercial execution, or expansion into new patient populations, while a decrease may signal increased competition, patent expiration risks, or loss of market share.
- How does CABOMETYX — total revenues compare across companies?
- Comparable to product-specific revenue lines for other biopharmaceutical companies, such as revenue from a lead oncology asset or a flagship therapeutic franchise.